270 related articles for article (PubMed ID: 20729419)
21. Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.
Beer L; Hochmair M; Haug AR; Schwabel B; Kifjak D; Wadsak W; Fuereder T; Fabikan H; Fazekas A; Schwab S; Mayerhoefer ME; Herold C; Prosch H
Clin Nucl Med; 2019 Jul; 44(7):535-543. PubMed ID: 31021918
[TBL] [Abstract][Full Text] [Related]
22. Comparison Between
Rossi G; Bauckneht M; Genova C; Rijavec E; Biello F; Mennella S; Dal Bello MG; Cittadini G; Bruzzi P; Piva R; Ceriani V; Sambuceti G; Lopci E; Morbelli S; Grossi F
J Nucl Med; 2020 Jul; 61(7):990-998. PubMed ID: 31806768
[TBL] [Abstract][Full Text] [Related]
23.
Fledelius J; Winther-Larsen A; Khalil AA; Bylov CM; Hjorthaug K; Bertelsen A; Frøkiær J; Meldgaard P
J Nucl Med; 2017 Dec; 58(12):1931-1937. PubMed ID: 28490472
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of erlotinib treatment response in non-small cell lung cancer using metabolic and anatomic criteria.
Stefano A; Russo G; Ippolito M; Cosentino S; Murè G; Baldari S; Sabini MG; Sardina D; Valastro LM; Bordonaro R; Messa C; Gilardi MC; Soto Parra H
Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):264-73. PubMed ID: 27463889
[TBL] [Abstract][Full Text] [Related]
25. Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Force J; Rajan A; Dombi E; Steinberg SM; Giaccone G
J Thorac Oncol; 2011 Jul; 6(7):1267-73. PubMed ID: 21610525
[TBL] [Abstract][Full Text] [Related]
26. Timing of metabolic response monitoring during erlotinib treatment in non-small cell lung cancer.
van Gool MH; Aukema TS; Schaake EE; Rijna H; Valdés Olmos RA; van Pel R; Burgers SA; van Tinteren H; Klomp HM;
J Nucl Med; 2014 Jul; 55(7):1081-6. PubMed ID: 24812245
[TBL] [Abstract][Full Text] [Related]
27. Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Sun JM; Ahn MJ; Park MJ; Yi JH; Kim TS; Chung MJ; Park YH; Ahn JS; Park K
Lung Cancer; 2010 Jul; 69(1):105-9. PubMed ID: 19959251
[TBL] [Abstract][Full Text] [Related]
28. Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.
Meng X; Loo BW; Ma L; Murphy JD; Sun X; Yu J
J Nucl Med; 2011 Oct; 52(10):1573-9. PubMed ID: 21903741
[TBL] [Abstract][Full Text] [Related]
29. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
30. Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
Binns DS; Pirzkall A; Yu W; Callahan J; Mileshkin L; Conti P; Scott AM; Macfarlane D; Fine BM; Hicks RJ;
Eur J Nucl Med Mol Imaging; 2011 Apr; 38(4):642-50. PubMed ID: 21207024
[TBL] [Abstract][Full Text] [Related]
31. Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients.
Watanabe H; Yamamoto S; Kunitoh H; Sekine I; Yamamoto N; Ohe Y; Tamura T; Kodama T; Sugimura K; Saijo N
Cancer Sci; 2003 Nov; 94(11):1015-20. PubMed ID: 14611681
[TBL] [Abstract][Full Text] [Related]
32. Targeted therapy in patients with non-small cell lung cancer previously treated with chemotherapy.
Drobnienė M; Cicėnienė A; Zelvienė TP; Grigienė R; Lachej N; Steponavičienė L; Aleknavičius E
Medicina (Kaunas); 2011; 47(9):520-5. PubMed ID: 22156604
[TBL] [Abstract][Full Text] [Related]
33. Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Giuliani J; Martelli S; Remo A; Bonetti A
Tumori; 2015 Jul; 101(4):e115-7. PubMed ID: 25953440
[TBL] [Abstract][Full Text] [Related]
34. Assessment of lung cancer response after nonoperative therapy: tumor diameter, bidimensional product, and volume. A serial CT scan-based study.
Werner-Wasik M; Xiao Y; Pequignot E; Curran WJ; Hauck W
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):56-61. PubMed ID: 11516851
[TBL] [Abstract][Full Text] [Related]
35. Revisiting the relationship between tumour volume and diameter in advanced NSCLC patients: An exercise to maximize the utility of each measure to assess response to therapy.
Nishino M; Jackman DM; DiPiro PJ; Hatabu H; Jänne PA; Johnson BE
Clin Radiol; 2014 Aug; 69(8):841-8. PubMed ID: 24857677
[TBL] [Abstract][Full Text] [Related]
36. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Riely GJ; Kris MG; Zhao B; Akhurst T; Milton DT; Moore E; Tyson L; Pao W; Rizvi NA; Schwartz LH; Miller VA
Clin Cancer Res; 2007 Sep; 13(17):5150-5. PubMed ID: 17785570
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Ma J; Wu X; Li J; Wang Z; Wang Y
J Investig Med; 2017 Jun; 65(5):935-941. PubMed ID: 28360035
[TBL] [Abstract][Full Text] [Related]
38. Is ¹⁸F-fluorodeoxyglucose positron emission tomography-based metabolic response superior to Response Evaluation Criteria In Solid Tumors-based response after two cycles of platinum-based chemotherapy in predicting clinical outcome of untreated patients with advanced non-small cell lung cancer?
Yang JJ; Wang SX; Zhong WZ; Xu CR; Yan HH; Wu YL
Nucl Med Commun; 2011 Dec; 32(12):1113-20. PubMed ID: 21934546
[TBL] [Abstract][Full Text] [Related]
39. Total Body Metabolic Tumor Response in ALK Positive Non-Small Cell Lung Cancer Patients Treated with ALK Inhibition.
Kerner GS; Koole MJ; Bongaerts AH; Pruim J; Groen HJ;
PLoS One; 2016; 11(5):e0149955. PubMed ID: 27137772
[TBL] [Abstract][Full Text] [Related]
40. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
